For the quarter ending 2025-09-30, TMDX made $143,823,000 in revenue. $24,319,000 in net income. Net profit margin of 16.91%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 143,823,000 | 157,370,000 | 143,537,000 | 110,926,333.333 |
| Product | 18,687,000 | 19,421,000 | - | - |
| Service | 40,561,000 | 41,360,000 | - | - |
| Total cost of revenue | 59,248,000 | 60,781,000 | 55,309,000 | 43,847,666.667 |
| Gross profit | 84,575,000 | 96,589,000 | 88,228,000 | 67,078,666.667 |
| Research, development and clinical trials | 15,260,000 | 15,934,000 | 17,160,000 | 13,900,666.667 |
| Selling, general and administrative | 46,015,000 | 44,088,000 | 43,625,000 | 41,987,000 |
| Total operating expenses | 61,275,000 | 60,022,000 | 60,785,000 | 55,887,666.667 |
| Income from operations | 23,300,000 | 36,567,000 | 27,443,000 | 11,191,000 |
| Interest expense | 3,491,000 | 3,476,000 | 3,461,000 | 3,597,333.333 |
| Interest income and other income (expense) | 3,222,000 | 3,091,000 | 2,694,000 | 2,918,000 |
| Total other income (expense), net | -269,000 | -385,000 | -767,000 | -679,333.333 |
| Income before income taxes | 23,031,000 | 36,182,000 | 26,676,000 | 10,511,666.667 |
| (provision) benefit for income taxes | -1,288,000 | 1,275,000 | 994,000 | 79,000 |
| Net income | 24,319,000 | 34,907,000 | 25,682,000 | 10,416,000 |
| Earnings per share, basic, total | 0.71 | 1.03 | 0.76 | 0.313 |
| Earnings per share, diluted, total | 0.66 | 0.92 | 0.7 | 0.297 |
| Weighted average common shares outstanding, diluted | 40,748,023 | 40,558,953 | 39,914,487 | -155,705 |
| Weighted average number of shares outstanding, basic, total | 34,112,452 | 33,912,669 | 33,721,603 | -70,480.333 |
TransMedics Group, Inc. (TMDX)
TransMedics Group, Inc. (TMDX)